AU2005226901B2 - Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury - Google Patents
Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury Download PDFInfo
- Publication number
- AU2005226901B2 AU2005226901B2 AU2005226901A AU2005226901A AU2005226901B2 AU 2005226901 B2 AU2005226901 B2 AU 2005226901B2 AU 2005226901 A AU2005226901 A AU 2005226901A AU 2005226901 A AU2005226901 A AU 2005226901A AU 2005226901 B2 AU2005226901 B2 AU 2005226901B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- phenyl
- formula
- group
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000020431 spinal cord injury Diseases 0.000 title claims abstract description 67
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 229940124530 sulfonamide Drugs 0.000 title claims abstract description 12
- -1 2-pyridyl-ethyl Chemical group 0.000 claims description 102
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 238000011084 recovery Methods 0.000 claims description 21
- 239000004480 active ingredient Substances 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 230000003902 lesion Effects 0.000 claims description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 9
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 9
- 125000003431 oxalo group Chemical group 0.000 claims description 9
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 9
- 125000005544 phthalimido group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 230000000451 tissue damage Effects 0.000 claims description 7
- 231100000827 tissue damage Toxicity 0.000 claims description 7
- 230000028266 oligodendrocyte apoptotic process Effects 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000001802 infusion Methods 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- URZONQSEPBBTSB-HNCPQSOCSA-N methanesulfonamide;(2r)-2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CS(N)(=O)=O.CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 URZONQSEPBBTSB-HNCPQSOCSA-N 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004248 oligodendroglia Anatomy 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000007115 recruitment Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- NTEURBORARLYJB-UHFFFAOYSA-N n-methylsulfonylpropanamide Chemical compound CCC(=O)NS(C)(=O)=O NTEURBORARLYJB-UHFFFAOYSA-N 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000005057 finger movement Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04007177.1 | 2004-03-25 | ||
| EP04007177A EP1579859B1 (en) | 2004-03-25 | 2004-03-25 | Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
| PCT/EP2005/002822 WO2005092315A1 (en) | 2004-03-25 | 2005-03-17 | Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005226901A1 AU2005226901A1 (en) | 2005-10-06 |
| AU2005226901B2 true AU2005226901B2 (en) | 2011-06-02 |
Family
ID=34854609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005226901A Ceased AU2005226901B2 (en) | 2004-03-25 | 2005-03-17 | Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090030083A1 (enExample) |
| EP (1) | EP1579859B1 (enExample) |
| JP (1) | JP4988550B2 (enExample) |
| KR (2) | KR101327150B1 (enExample) |
| CN (2) | CN103054842A (enExample) |
| AT (1) | ATE347883T1 (enExample) |
| AU (1) | AU2005226901B2 (enExample) |
| BR (1) | BRPI0509167A (enExample) |
| CA (1) | CA2555162C (enExample) |
| CY (1) | CY1107562T1 (enExample) |
| DE (1) | DE602004003673T2 (enExample) |
| DK (1) | DK1579859T3 (enExample) |
| ES (1) | ES2279248T3 (enExample) |
| IL (1) | IL177169A (enExample) |
| MX (1) | MXPA06009085A (enExample) |
| NO (1) | NO20064793L (enExample) |
| NZ (1) | NZ548917A (enExample) |
| PL (1) | PL1579859T3 (enExample) |
| PT (1) | PT1579859E (enExample) |
| RU (1) | RU2396075C2 (enExample) |
| SI (1) | SI1579859T1 (enExample) |
| WO (1) | WO2005092315A1 (enExample) |
| ZA (1) | ZA200608517B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2664359A1 (en) * | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| CN103172547B (zh) * | 2011-12-20 | 2016-10-12 | 天津市国际生物医药联合研究院 | 磺酰胺衍生物的制备及其应用 |
| CN103159674A (zh) * | 2013-04-03 | 2013-06-19 | 苏州安诺生物医药技术有限公司 | 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途 |
| KR20220064039A (ko) | 2020-11-11 | 2022-05-18 | 정성삼 | 척수 손상 예방 또는 치료용 조성물 |
| KR102320780B1 (ko) | 2021-01-29 | 2021-11-02 | 정성삼 | 척추 통증 완화 및 척추 유연성 개선을 위한 조성물 및 이의 제조방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010016195A1 (en) * | 1999-02-24 | 2001-08-23 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
| WO2002062330A2 (en) * | 2001-02-02 | 2002-08-15 | Dompé S.p.A. | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| EP1123276B1 (en) * | 1998-10-23 | 2003-01-08 | Dompe' S.P.A. | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1318466B1 (it) * | 2000-04-14 | 2003-08-25 | Dompe Spa | Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria. |
-
2004
- 2004-03-25 EP EP04007177A patent/EP1579859B1/en not_active Expired - Lifetime
- 2004-03-25 ES ES04007177T patent/ES2279248T3/es not_active Expired - Lifetime
- 2004-03-25 PL PL04007177T patent/PL1579859T3/pl unknown
- 2004-03-25 SI SI200430194T patent/SI1579859T1/sl unknown
- 2004-03-25 AT AT04007177T patent/ATE347883T1/de active
- 2004-03-25 DK DK04007177T patent/DK1579859T3/da active
- 2004-03-25 PT PT04007177T patent/PT1579859E/pt unknown
- 2004-03-25 DE DE602004003673T patent/DE602004003673T2/de not_active Expired - Lifetime
-
2005
- 2005-03-17 KR KR1020127023407A patent/KR101327150B1/ko not_active Expired - Fee Related
- 2005-03-17 CA CA2555162A patent/CA2555162C/en not_active Expired - Fee Related
- 2005-03-17 NZ NZ548917A patent/NZ548917A/en not_active IP Right Cessation
- 2005-03-17 CN CN2012104176511A patent/CN103054842A/zh active Pending
- 2005-03-17 WO PCT/EP2005/002822 patent/WO2005092315A1/en not_active Ceased
- 2005-03-17 RU RU2006137575/15A patent/RU2396075C2/ru not_active IP Right Cessation
- 2005-03-17 CN CNA2005800095602A patent/CN1933825A/zh active Pending
- 2005-03-17 US US10/588,454 patent/US20090030083A1/en not_active Abandoned
- 2005-03-17 JP JP2007504310A patent/JP4988550B2/ja not_active Expired - Fee Related
- 2005-03-17 AU AU2005226901A patent/AU2005226901B2/en not_active Ceased
- 2005-03-17 MX MXPA06009085A patent/MXPA06009085A/es active IP Right Grant
- 2005-03-17 KR KR1020067018031A patent/KR101312235B1/ko not_active Expired - Fee Related
- 2005-03-17 BR BRPI0509167-5A patent/BRPI0509167A/pt active Search and Examination
-
2006
- 2006-07-31 IL IL177169A patent/IL177169A/en not_active IP Right Cessation
- 2006-10-12 ZA ZA2006/08517A patent/ZA200608517B/en unknown
- 2006-10-23 NO NO20064793A patent/NO20064793L/no not_active Application Discontinuation
-
2007
- 2007-02-22 CY CY20071100248T patent/CY1107562T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1123276B1 (en) * | 1998-10-23 | 2003-01-08 | Dompe' S.P.A. | N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| US20010016195A1 (en) * | 1999-02-24 | 2001-08-23 | Tobinick Edward L. | Cytokine antagonists for the treatment of localized disorders |
| WO2002062330A2 (en) * | 2001-02-02 | 2002-08-15 | Dompé S.p.A. | Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1579859T3 (da) | 2007-04-10 |
| ATE347883T1 (de) | 2007-01-15 |
| KR20070018015A (ko) | 2007-02-13 |
| KR101327150B1 (ko) | 2013-11-06 |
| DE602004003673T2 (de) | 2007-10-04 |
| RU2006137575A (ru) | 2008-04-27 |
| MXPA06009085A (es) | 2007-04-02 |
| ES2279248T3 (es) | 2007-08-16 |
| WO2005092315A1 (en) | 2005-10-06 |
| NO20064793L (no) | 2006-10-23 |
| NZ548917A (en) | 2010-06-25 |
| CY1107562T1 (el) | 2013-03-13 |
| KR20120104445A (ko) | 2012-09-20 |
| KR101312235B1 (ko) | 2013-09-26 |
| CA2555162C (en) | 2012-11-27 |
| US20090030083A1 (en) | 2009-01-29 |
| DE602004003673D1 (de) | 2007-01-25 |
| IL177169A (en) | 2010-12-30 |
| EP1579859A1 (en) | 2005-09-28 |
| CA2555162A1 (en) | 2005-10-06 |
| AU2005226901A1 (en) | 2005-10-06 |
| EP1579859B1 (en) | 2006-12-13 |
| RU2396075C2 (ru) | 2010-08-10 |
| PT1579859E (pt) | 2007-03-30 |
| JP2007530478A (ja) | 2007-11-01 |
| SI1579859T1 (sl) | 2007-04-30 |
| CN1933825A (zh) | 2007-03-21 |
| CN103054842A (zh) | 2013-04-24 |
| BRPI0509167A (pt) | 2007-09-11 |
| ZA200608517B (en) | 2008-04-30 |
| IL177169A0 (en) | 2006-12-10 |
| PL1579859T3 (pl) | 2007-06-29 |
| JP4988550B2 (ja) | 2012-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003535034A (ja) | ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法 | |
| KR19990044182A (ko) | 말초 활성 통각과민 치료용 아편제 | |
| JP2004508404A (ja) | 鎮痛手法 | |
| RU2299731C2 (ru) | Агонисты никотиновых рецепторов для лечения воспалительных заболеваний | |
| CA3213864A1 (en) | Dosing regimen of tradipitant | |
| US11738040B2 (en) | Composition for treating joint disease and kit containing same | |
| JP6650650B2 (ja) | 神経系疾患治療剤 | |
| JP2003176240A (ja) | ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法 | |
| AU2005226901B2 (en) | Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| EP1806136B1 (en) | Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy | |
| Smith et al. | Type II collagen-induced arthritis in the diabetic-resistant biobreeding rat: inflammatory and histopathological features of joint pathology and effects of antiinflammatory and antirheumatic drugs on this chronic arthritic process. | |
| HK1184385A (en) | Use of n-(2-aryl-propionyl)-sulfonamides for the preparation of a medicament for the treatment of spinal cord injury | |
| US7439270B2 (en) | Drugs for spinal anesthesia | |
| HK1101358A (en) | Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury | |
| Baine | The Effects of Sex on Spinal Cord Injury Recovery Following Noxious Input | |
| NZ242863A (en) | Pharmaceutical compositions comprising atipamezole[4-(2-ethyl-2,3-dihydro-1h-inden-2-yl)-1h-imidazole] | |
| CZ20013048A3 (cs) | Terapeutický prostředek proti bolesti v lýtkových svalech při chůzi | |
| KR20100015014A (ko) | 프레가발린을 포함하는 척수 손상을 예방 및 치료하는약제학적 조성물 | |
| JP2003522792A (ja) | 薬剤調製用化合物の用途 | |
| Sorbera | RDP-58 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |